Clinical Trial Update: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) [Phase 2]

View source ↗

Summary

Open-label, multicenter Phase 2 study evaluating eribulin mesylate in previously treated advanced or metastatic soft tissue sarcoma; the trial is completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-28